Recital 10, Commission Delegated Regulation (EU) No 357/2014 of 3 February 2014 supplementing Direct…

In forcesince 3 Feb 2014

During the life cycle of an authorised medicinal product, a significant change may occur in the standard of care for the diagnosis, treatment or prevention of a disease, leading to the need to re-open discussions on the established benefit-risk balance of the medicinal product. The European Court of Justice has ruled that a modified consensus within the medical community regarding the appropriate assessment criteria of the therapeutic efficacy of a medicinal product may constitute concrete and objective factors capable of acting as a basis for the finding of a negative benefit-risk assessment of that product [Case C-221/10P Artegodan v Commission, not yet published, paragraphs 100-103.]. It may therefore be necessary to provide new evidence on the efficacy of the medicinal product to maintain a positive benefit-risk assessment. Likewise, if an improved understanding of the disease or the pharmacology of a medicinal product has brought into question the criteria used to establish the efficacy of the medicinal product at the time the marketing authorisation was granted, additional studies may be considered.

  • Judgment of the Court (Third Chamber), 19 April 2012. Artegodan GmbH v European Commission.Decision

    19 Apr 2012 · 62010CJ0221